Full-length article|Articles in Press

Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study

Published:March 12, 2023DOI:


      Background aims

      Before autologous stem cell transplantation (ASCT), hematopoietic stem cells must be stimulated to move from the bone marrow to the peripheral blood for harvesting. Plerixafor, a C-X-C chemokine receptor type 4 antagonist, is used to increase stem cell harvests. However, the effects of plerixafor on post-ASCT outcomes remain unclear.


      In a dual-center retrospective cohort study of 43 Japanese patients who received ASCT, the authors compared transplantation outcomes in patients who underwent stem cell mobilization with granulocyte colony-stimulating factor with (n = 25) or without (n = 18) plerixafor.


      The number of days to neutrophil and platelet engraftment was significantly shorter with plerixafor than without plerixafor, as assessed by univariate (neutrophil, P = 0.004, platelet, P = 0.002), subgroup, propensity score matching and inverse probability weighting analyses. Although the cumulative incidence of fever was comparable with or without plerixafor (P = 0.31), that of sepsis was significantly lower with plerixafor than without (P < 0.01). Thus, the present data indicate that plerixafor leads to earlier neutrophil and platelet engraftment and a reduction of infectious risk.


      The authors conclude that plerixafor may be safe to use and that it reduces the risk of infection in patients with a low CD34+ cell count the day before apheresis.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cavo M
        • Rajkumar SV
        • Palumbo A
        • Moreau P
        • Orlowski R
        • et al.
        International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
        Blood. 2011; 117: 6063-6073
        • Kumar SK
        • Dispenzieri A
        • Lacy MQ
        • Gertz MA
        • Buadi FK
        • et al.
        Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
        Leukemia. 2014; 28: 1122-1128
        • Gisselbrecht C
        • Bosly A
        • Lepage E
        • Reyes F
        • Philip T
        • et al.
        Autologous hematopoietic stem cell transplantation in intermediate and high grade non-Hodgkin's lymphoma: a review.
        Ann Oncol. 1993; 4: 7-13
        • Jantunen E.
        Autologous stem cell transplantation beyond 60 years of age.
        Bone Marrow Transplant. 2006; 38: 715-720
        • Vose JM
        • Ho AD
        • Coiffier B
        • Corradini P
        • Khouri I
        • et al.
        Advances in mobilization for the optimization of autologous stem cell transplantation.
        Leuk Lymphoma. 2009; 50: 1412-1421
        • Giralt S
        • Costa L
        • Schriber J
        • Dipersio J
        • Maziarz R
        • et al.
        Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
        Biol Blood Marrow Transplant. 2014; 20: 295-308
        • Jagannath S
        • Vesolo DH
        • Glenn L
        • Crowley J
        • Barlogie B.
        Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
        Blood. 1992; 80: 1666-1672
        • Teshima T
        • Harada M
        • Takamatsu Y
        • Makino K
        • Taniguchi S
        • et al.
        Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting.
        Bone Marrow Transplant. 1992; 10: 215-220
        • Arora S
        • Majhail NS
        • Liu H.
        Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
        Clin Lymphoma Myeloma Leuk. 2019; 19: 200-205
        • Hsu YM
        • Cushing MM.
        Autologous Stem Cell Mobilization and Collection.
        Hematol Oncol Clin North Am. 2016; 30: 573-589
        • Wang J
        • Tannous BA
        • Poznansky MC
        • Chen H.
        CXCR4 antagonist AMD3100 (plerixafor): from an impurity to a therapeutic agent.
        Pharmacol Res. 2020; 159105010
        • Bilgin YM
        • de Greef GE.
        Plerixafor for stem cell mobilization: the current status.
        Curr Opin Hematol. 2016; 23: 67-71
        • Kessans MR
        • Gatesman ML
        • Kockler DR.
        Plerixafor: a peripheral blood stem cell mobilizer.
        Pharmacotherapy. 2010; 30: 485-492
        • Steinberg M
        • Plerixafor Silva M.
        A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
        Clin Ther. 2010; 32: 821-843
        • Chow E
        • Rao K V
        • Wood W A
        • Covington D
        • Armistead P M
        • et al.
        Effectiveness of an alogorithm-based approach to the utilization of plerixafor in patients undergoing chemotherapy-based stem cell mobilization.
        Biol Blood Marrow Transplant. 2014; 20: 1064-1068
        • Maechler M
        • Bacher U
        • Daskalakis M
        • Nilius H
        • Nagler M
        • et al.
        Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.
        Hematol Oncol. 2022;
        • Sharma A
        • Leonard A
        • West K
        • Gossett JM
        • Uchida N
        • et al.
        Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease.
        Br J Haematol. 2022; 198: 740-744
        • Du Toit J
        • Goeijenbier M
        • du Toit C
        • de Witt P
        • Koornhof H
        • et al.
        Predictors of poor haematopoietic stem cell mobilisation in patients with haematological malignancies at a South African centre.
        Transfus Apher Sci. 2022; 61: 103419
        • Yang C
        • Dehghani M
        • Hopman W
        • Bhella S.
        Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: a single center comparison of GCSF+/– plerixafor vs cyclophosphamide/GCSF+/– plerixafor.
        J Clin Apher. 2022; 37: 348-353
        • DiPersio J F
        • Ho A D
        • Hanrahan J
        • Hsu F J
        • Fruehauf S.
        Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting.
        Biol Blood Marrow Transplant. 2011; 17: 943-955
      1. N Tsukada, M Nishikori, H Goto, R Kanamori, S Nishina, et al. Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study. Drugs Real World Outcomes. 2022; 9(1): 63-78.

        • Ardakani M T
        • Ahadi H R
        • Bonakchi H
        • Parkhideh S
        • Tavakoli F
        • et al.
        Evaluation of CD34+ Cell Count at Different Time Points Following Plerixafor Administration in Autologous Hematopoietic Stem Cell Transplantation.
        Int J Cancer Manage. 2022; 15e120241
        • Takano T.
        The vision of Japanese guidelines for the proper use of G-CSF and future perspective.
        Ann Oncol. 2016; 27: 1257-1266
        • Mohty M
        • Hubel K
        • Kroger N
        • Alijurf M
        • Aooerley J
        • Basak G W
        • et al.
        Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
        Bone Marrow Transplant. 2014; 49: 865-872
        • Cheson BD
        • Pfistner B
        • Juweid ME
        • Gascoyne RD
        • Specht L
        • et al.
        Revised response criteria for malignant lymphoma.
        J Clin Oncol. 2007; 25: 579-586
        • International Myeloma Working Group
        Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
        Br J Haematol. 2003; 121: 749-757
        • Michael PF.
        Two-sided Exact Tests and Matching Confidence Intervals for Discrete Data.
        R Journal. 2010; 20: 53-58
        • Fujii K
        • Nm Fujii
        • Kondo T
        • Mitsuhashi T
        • Nakamura M
        • et al.
        Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection.
        Transfus Apher Sci. 2021; 60103147
        • Gooley T A
        • Leisenring W
        • Crowley J
        • Storer B E
        • et al.
        Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.
        Stat Med. 1999; 18: 695-706
        • Kanda Y
        Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics.
        Bone Marrow Transplant. 2013; 48: 452-458
        • Wang M H
        • Chang S H
        Nonparametric Estimation of a Recurrent Survival Function.
        J Am Stat Assoc. 1999; 94: 146-153
        • Ishii A
        • Jo T
        • Arai Y
        • Oshima S
        • Kanda J
        • et al.
        Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
        Cytotherapy. 2022; 24: 49-58
        • Duong HK, Savani BN, Copelan E, Devine S, Costa LJ
        • et al.
        Bone Marrow Transplant. 2014; 20: 1262-1273
        • Antelo ML
        • Altuna A
        • Gimeno JJ
        • Ferreiro JJ
        • Amunarriz C
        • et al.
        Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with plerixafor: a retrospective, multicenter study of a large series of patients.
        Transfus Apher Sci. 2021; 60103130
        • Varmavuo V
        • Rimpilanen J
        • Kuitunen H
        • Nihtinen A
        • Vasala K
        • et al.
        Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.
        Transfusion. 2014; 54: 1243-1250
      2. Yogo T, Tsukada N, Nashimoto J, Uto Y, Sato K, et al. Plerixafor-mobilized patients have a high risk of non-infectious fever during engraftment after autologous peripheral blood stem cell transplantation. 45th Annual Meeting of the European Society for Blood and Marrow Transplantation. 24–27 March 2019.

        • Maiolino A
        • Biasolo I
        • Lima J
        • Portugal AC
        • Pulcheri W
        • et al.
        Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria.
        Bone Marrow Transplant. 2003; 31: 393-397
        • Chen K Y
        • Bucci T G
        • Shaw J R
        • Alexander M D
        • Grgic T
        • et al.
        Plerixafor strategies for autologous hematopoietic cell transplant mobilization: a comparison of efficacy and cost.
        Transfus Apher Sci. 2022; 61103303
        • Micallef IN
        • Stiff PJ
        • Nademanee AP
        • Maziarz RT
        • Horwitz ME
        • et al.
        Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
        Biol Blood Marrow Transplant. 2018; 24: 1187-1195
        • Sureda A
        • Chabannon C
        • Masszi T
        • Pohlreich D
        • Scheid C
        • et al.
        Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.
        Bone Marrow Transplant. 2020; 55: 613-622
        • Valtola J
        • Silvennoinen R
        • Ropponen A
        • Siltonen T
        • Saily M
        • et al.
        Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
        Leuk Lymphoma. 2019; 60: 453-461
        • Kaur S
        • Raggatt LJ
        • Millard SM
        • Wu AC
        • Batoon L
        • et al.
        Self-repopulating recipient bone marrow resident macrophages promote long-term hematopoietic stem cell engraftment.
        Blood. 2018; 132: 735-749
        • Jeannet R
        • Cai Q
        • Liu H
        • Vu H
        • Kuo YH.
        Alcam regulates long-term hematopoietic stem cell engraftment and self-renewal.
        Stem Cells. 2013; 31: 560-571
        • Cheng CW
        • Adams GB
        • Perin L
        • Wei M
        • Zhou X
        • et al.
        Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression.
        Cell Stem Cell. 2014; 14: 810-823
        • Mendelsohn AR
        • Larrick JW.
        Prolonged fasting/refeeding promotes hematopoietic stem cell regeneration and rejuvemation.
        Rejuvenation Res. 2014; 17: 385-389
        • Garderet L
        • Labopin M
        • Gorin NC
        • Polge E
        • Fouillard L
        • et al.
        Patients with lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow.
        Bone Marrow Transplant. 2003; 31: 23-29
        • Shinzato A
        • Tabuchi K
        • Atsuta Y
        • Inoue M
        • Inagaki J
        • et al.
        PBSCT is associated with poorer survival and increased chronic GVHD than BMT in Japanese pediatric patients with acute leukemia and an HLA-matched sibling donor.
        Pediatr Blood Cancer. 2013; 60: 1513-1519
        • Gahrton G
        • Iacobelli S
        • Bandini G
        • Björkstrand B
        • Corradini P
        • et al.
        Peripheral blood or bone marrow cells in reduced intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
        Haematologica. 2017; 92: 1513-1518
        • Retting AR
        • Ihorst G
        • Bertz H
        • Lübbert M
        • Marks R
        • et al.
        Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
        Ann Hematol. 2021; 100: 2339-2350
        • Majolino I
        • Cavallaro AM
        • Schime R.
        Peripheral blood stem cells for allogeneic transplantation.
        Bone Marrow Transplant. 1996; 18: 171-174
        • Chatterjee S
        • Azad BB
        • Nimmagadda S.
        The intricate role of CXCR4 in cancer.
        Adv Cancer Res. 2014; 124: 31-82
        • Bianchi M E
        • Mezzapelle R.
        The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration.
        Front Immunol. 2020; 11: 2109
        • Furusato B
        • Mohamed A
        • Uhlen M
        • Rhim JS.
        CXCR4 and cancer.
        Pathol Int. 2010; 60: 497-505
        • Kucia M
        • Reca R
        • Miekus K
        • Wanzeck J
        • Wojakowski W
        • et al.
        Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms; pivotal role of the SDF-1-CXCR4 axis.
        Stem Cells. 2005; 23: 879-894
        • Wang S
        • Wang L
        • Chen SW.
        Pan-cancer analysis of CXCR4 carcinogenesis in human tumors.
        Transl Cancer Res. 2021; 10: 4180-4195
        • Berchanski A
        • Kalinkovich A
        • Ludin A
        • Lapidot T
        • Lapidot A.
        Insights into the mechanism of enhanced mobilization of hematopoietic progenitor cells and release of CXCL12 by a combination of AMD3100 and aminoglycoside-polyarginine conjugates.
        FEBS J. 2011; 278: 4150-4165
        • Benedicto A
        • Romayor I
        • Arteta B.
        CXCR4 receptor blockage reduced the contribution of tumor and stromal cells to the metastatic growth in the liver.
        Oncol Rep. 2018; 39: 2022-2030
        • Chen L
        • Ouyang J
        • Wienand K
        • Bojarczuk K
        • Hao Y
        • et al.
        CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
        Haematologica. 2020; 105: 1361-1368
        • Weber TS.
        Cell Cycle-Associated CXCR4 Expression in Germinal Center B Cells and Its Implications on Affinity Maturation.
        Front Immunol. 2018; 9: 1313
        • Falgas A
        • Pallares V
        • Unzueta U
        • Nunez Y
        • Sierra J
        • et al.
        Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells.
        Int J Nanomedicine. 2021; 16: 1869-1888
        • Jang JW
        • Thuy PX
        • Lee JW
        • Moon EY.
        CXCR4 promotes B cell viability by the cooperation of nuclear factor (erythroid-derived 2)-like 2 and hypoxia-inducible factor-1α under hypoxic conditions.
        Cell Death Dis. 2021; 12: 330
        • Müller A
        • Homey B
        • Soto H
        • Ge N
        • Catron D
        • et al.
        Involvement of chemokine receptors in breast cancer metastasis.
        Nature. 2021; 410: 50-56
        • Mortezaee K.
        CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis.
        Life Sci. 2020; 249117534
        • Yagi H
        • Tan W
        • Dillenburg-Pilla P
        • Armando S
        • Amornphimoltham P
        • et al.
        A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.
        Sci Signal. 2011; 4: ra60
        • Liekens S
        • Schols D
        • Hatse S.
        CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.
        Curr Pharm Des. 2010; 16: 3903-3920
        • Moreno MJ
        • Bosch R
        • Dieguez-Gonzalez R
        • Novelli S
        • Mozos A
        • et al.
        CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.
        J Pathol. 2015; 235: 445-455